ultra mega lower bicutan
A Tennessee man is convicted of killing 2 at a high school basketball game in 2021
Forget $4 trillion, darling of Wall Street Nvidia's market cap could hit $5 trillion; Dan Ives gives this explanation
In less than a fortnight after Apple released its long-awaited Apple Intelligence AI features in countries such as Australia and the UK, there are already calls for it to kill one of the platform’s key features to summarise notifications. On 13 December, the BBC complained to Apple following a summary generated by the AI feature of news notifications announced the suicide of Luigi Mangione, the main suspect in the murder of the CEO of UnitedHealthcare. The AI-powered summary falsely claimed BBC News had published an article claiming Mangione had shot himself – which was completely false. Now, the group Reporters Without Borders has called on Apple to remove the technology saying that the generative AI feature is “threatening reliable journalism”. The journalism body said that it was very concerned about the risks posed to media outlets by the AI technology which “is incapable of producing reliable information in a consistent, trustworthy manner.” In a statement it added that the incident should illustrate that “generative AI services are still too immature to produce reliable information for the public, and should not be allowed on the market for such uses.” “AIs are probability machines, and facts can’t be decided by a roll of the dice. RSF calls on Apple to act responsibly by removing this feature,” said Vincent Berthier, Head of RSF’s Technology and Journalism Desk. “The automated production of false information attributed to a media outlet is a blow to the outlet’s credibility and a danger to the public’s right to reliable information on current affairs.” Apple is yet to comment on the entire episode. The company’s Apple Intelligence notification summary feature allows users to group notifications. It claims that customers might find this feature useful to help reduce the interruptions caused by ongoing notifications. However, even before the BBC complained, another instance of news being distorted and falsely reported in the summaries came to light in November. On 21 November, three articles from the New York Times were reportedly grouped together in one notification – with one part claiming “Netanyahu arrested”, in reference to the Israeli prime minister. That false summary was generated after the AI feature summarised a report about the International Criminal Court issuing an arrest warrant for Netanyahu.NoneNow that Dragon Age: The Veilguard is in players' hands, many BioWare fans are already looking ahead to what's to come with the developer's upcoming project Mass Effect 5 . And BioWare project director and executive producer Michael Gamble recently shared a recommendation for what new fans should experience when getting into the sci-fi series. In a post on the social media site formerly known as Twitter, Gamble suggested fans should revisit the infamous Mass Effect 2 DLC Lair of the Shadow Broker. So far, details on the next Mass Effect are slim aside from a teaser poster and an early reveal trailer showing the familiar N7 logo and a returning Liara T'soni, which makes Lair of the Shadow Broker a particularly interesting suggestion. As a refresher, Lair of the Shadow Broker is a DLC mission pack for Mass Effect 2 focusing on Liara T'Soni's quest to find and hunt down the elusive Shadow Broker, the leader of a mysterious black market organization with access to vital information that high-profile clients pay to gain access to. The DLC mission is perhaps best played as a post-game quest, which saw players reunite with Liara from the original Mass Effect, continuing her story and a possible relationship if players formed a bond with her previously. What makes the Lair of the Shadow Broker mission so vital is that it carried over into Mass Effect 3, which saw – sorry for spoiling – Liara assume the role of the Shadow Broker and take over the organization in secret. Given that Liara is one of the characters highlighted in the Mass Effect 5 teaser and that she's become one of the most influential people in the galaxy in her new role, it should stand to reason that her part in the post-Reaper invasion of the galaxy will be a large one. While some community members are still sore about Andromeda being left unresolved in favor of a sequel to the original trilogy, it is interesting to see BioWare looking to continue with threads and a new storyline following Mass Effect 3's still-controversial ending. If you're looking for another RPG to play along with Dragon Age: The Veilguard and the Mass Effect series, check out our roundup of the best RPGs to play right now.
The US provided no evidence that China manipulates TikTok content inside the country, court says
DETROIT (AP) — Brandon Noel's 26 points helped Wright State defeat Detroit Mercy 80-72 on Saturday. Noel had seven rebounds for the Raiders (6-5, 1-1 Horizon League). Jack Doumbia scored 21 points while shooting 8 of 16 from the field and 5 for 6 from the line and added 13 rebounds and three blocks. Alex Huibregste shot 5 of 10 from the field, including 2 for 6 from 3-point range, and went 5 for 5 from the line to finish with 17 points, while adding six assists. The Titans (5-6, 1-1) were led in scoring by Orlando Lovejoy, who finished with 14 points, seven rebounds, four assists and two steals. Detroit Mercy also got 12 points from Nate Johnson. Grant Gondrezick II also recorded 11 points and two steals. Wright State's next game is Wednesday against Marshall at home. Detroit Mercy visits Davidson on Saturday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .DUNNES Stores fans are rushing to buy a new "classic" cable cardigan which is available in two colours - and it's perfect for cosy winter days. The Gallery Pearl Cable Detail Cardigan is available in stores and online now. It is priced at just €30 and comes in red and tan. Dunnes Stores said: "This round neck cardigan from Gallery boasts a classic cable knit pattern that adds some texture to your everyday looks. "Gallery is available exclusively at Dunnes Stores." It features dainty pearl embellishments and a tonal button throughout the design. And it can be paired with jeans for a cosy and comfortable look. Meanwhile, a fashion fan has told how she found a major designer dupe at Dunnes Stores - and it's €175 cheaper. Rebecca Hadden, @rebeccahadden on Instagram, alerted her followers to her latest discovery. She found a striking dupe for a high-end Meshki blazer and skirt set at her local branch. The Meshki outfit would otherwise set shoppers back over €230. In the post, she revealed she’d been eyeing the Meshki blazer and skirt for months. Rebecca said she was drawn to its structured fit, chic check pattern, and elegant gold button. In her TikTok, Rebecca showed off the new Dunnes Stores Heritage Check Blazer, priced at just €40. She paired it with the matching Heritage Mini Skirt, which costs only €20. "This looks good," she shared, pointing out the check pattern and gold buttons as highlights of the affordable dupe. “I know it’s obviously not going to be the exact same quality—no shoulder pads, no cinched waist—but come on, this is a pretty good dupe!” The Dunnes blazer has a double-breasted style with a heritage check pattern and two faux flap pockets. It’s a versatile piece that can work for both office wear and casual outings. Available in sizes 8 to 22 in stores, the blazer’s online stock has already started to dwindle with only sizes 8, 10, 12, 14 and 20 in stock online. The matching mini skirt, available in sizes 8 to 18, completes the ensemble. Dunnes Stores styled it with a simple black top and knee-high boots for a sleek look.None
Vancouver City Council to consider 5.5% property tax increase for 2025ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 Investors@transmedics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/transmedics-appoints-gerardo-hernandez-as-chief-financial-officer-and-provides-updated-2024-financial-outlook-302320060.html SOURCE TransMedics Group, Inc.NEW HOPE, Pa. (AP) — Dayle Haddon, a Canadian-born actor, activist and trailblazing former “Sports Illustrated” model who pushed back against age discrimination by reentering the industry as a widow, has died in a Pennsylvania home from what authorities believe was carbon monoxide poisoning. Authorities in Bucks County found Haddon, 76, dead in a second-floor bedroom Friday morning after emergency dispatchers were notified about a person unconscious at the Solebury Township home. A 76-year-old man police later identified as Walter J. Blucas of Erie was hospitalized in critical condition. Responders detected a high level of carbon monoxide in the property and township police said Saturday that investigators determined that “a faulty flue and exhaust pipe on a gas heating system caused the carbon monoxide leak.” Two medics were taken to a hospital for carbon monoxide exposure and a police officer was treated at the scene. As a model, Haddon appeared on the covers of Vogue, Cosmopolitan, Elle and Esquire in the 1970s and 1980s, as well as the 1973 Sports Illustrated swimsuit issue. She also appeared in about two dozen films from the 1970s to 1990s, according to IMDb.com, including 1994’s “Bullets Over Broadway,” starring John Cusack. Haddon left modeling after giving birth to her daughter, Ryan, in the mid-1970s, but then had to reenter the workforce after her husband’s 1991 death. This time she found the modeling industry far less friendly: “They said to me, ‘At 38, you’re not viable,’” Haddon told The New York Times in 2003. Working a menial job at an advertising agency, Haddon began reaching out to cosmetic companies, telling them there was a growing market to sell beauty products to aging baby boomers. She eventually landed a contract with Clairol, followed by Estée Lauder and then L’Oreal, for which she promoted the company’s anti-aging products for more than a decade. She also hosted beauty segments for CBS’s “The Early Show.” “I kept modeling, but in a different way,” she told The Times, “I became a spokesperson for my age.” In 2008, Haddon founded WomenOne, an organization aimed at advancing educational opportunities for girls and women in marginalized communities, including Rwanda, Haiti and Jordan.’ Haddon was born in Toronto and began modeling as a teenager to pay for ballet classes — she began her career with the Canadian ballet company Les Grands Ballet Canadiens, according to her website . Haddon’s daughter, Ryan, said in a social media post that her mother was “everyone’s greatest champion. An inspiration to many.” “A pure heart. A rich inner life. Touching so many lives. A life well lived. Rest in Light, Mom,” she said. The Associated Press
The Sparks will open the 2025 WNBA season on Friday, May 16, in San Francisco against the expansion Golden State Valkyries at the Chase Center, the league announced on Monday. After a historic 2024 season in which the WNBA had its most-watched regular season in 24 years while drawing the most spectators in two decades, the league is expanding its schedule again – this time to 44 games. WNBA teams played 40 games each of the last two seasons and 36 before then. The Sparks and new head coach Lynne Roberts will play their home opener on Sunday, May 18, against the 2024 WNBA runner-up Minnesota Lynx. The Sparks face the defending champion New York Liberty at home on Aug. 12 and in Brooklyn on July 3 and July 26. “We look forward to tipping off the WNBA’s 29th season in May of 2025 and continuing to build on the success of last season, when the WNBA delivered its most-watched draft and All-Star Game and set records for viewership, attendance, digital consumption and merchandise sales,” WNBA commissioner Cathy Engelbert said. “We look forward to the expansion Golden State Valkyries taking the court for the first time.” The Valkyries, who join the league as its 13th team and will be coached by former Marina High and UCLA star Natalie Nakase , have their expansion draft on Friday (3:30 p.m. PT). Golden State will pick fifth in the 2025 WNBA Draft in April. The Sparks, who finished last in the league in 2024 and have missed the postseason for four consecutive years, have the No. 2 selection in the April draft . The New York Liberty will celebrate their first title with a ring and banner ceremony on May 17 when they host the Las Vegas Aces, who they met in the 2023 WNBA Finals. The Liberty, who beat Minnesota in five games in last season’s Finals in October, will face the Lynx four times in 2025: in Minneapolis on July 30 and Aug. 16, and in New York on Aug. 10 and Aug. 19. The Indiana Fever and 2024 WNBA Rookie of the Year Caitlin Clark visit Los Angeles to take on the Sparks on Aug. 5 and Aug. 29 at Crypto.com Arena. The All-Star Game will be held in Indianapolis for the first time on July 19. Related Articles The games designated for the Commissioner’s Cup standings will be played from June 1-17. Each team plays the others in its conference – five games for the six Eastern Conference teams and six for the seven Western Conference teams. The top teams in each conference meet in the Cup title game on July 1, hosted by team with the best winning percentage in Cup play. The regular season ends on Sept. 11 with the expanded playoffs to take place after that. The WNBA Finals have been expanded to a best-of-seven series this year and the best-of-three opening round of the playoffs will switch to a 1-1-1 format, guaranteeing each team gets at least one home game. In the past, the team with the better seed would host the first two games. The semifinals remain best-of-five. The league will hold its draft on April 14 with Connecticut star Paige Bueckers expected to go first to the Dallas Wings. Free agency precedes that. Teams can begin negotiating with free agents on Jan. 21, and can start signing players on Feb. 1. The television and streaming broadcast schedule will be announced in 2025, likely in March. May 16 – at Golden State, 7 p.m. May 18 – vs. Minnesota, 3 p.m. May 21 – at Las Vegas, 7 p.m. May 23 – vs. Golden State, 7 p.m. May 25 – vs. Chicago, 3 p.m. May 27 – vs. Atlanta, 7 p.m. May 30 – at Las Vegas, 7 p.m. June 1 – vs. Phoenix, 3 p.m. June 6 – vs. Dallas, 6:30 p.m. June 9 – vs. Golden State, 7 p.m. June 11 – at Las Vegas, 7 p.m. June 14 – at Minnesota, 10 a.m. June 17 – vs. Seattle, 7 p.m. June 21 – at Minnesota, 5 p.m. June 24 – at Chicago, 5 p.m. June 26 – at Indiana, 4 p.m. June 29 – vs. Chicago, 3 p.m. July 3 – at New York, 4 p.m. July 5 – at Indiana, 4 p.m. July 10 – vs. Minnesota, noon July 13 – vs. Connecticut, 3 p.m. July 15 – vs. Washington, 7 p.m. July 22 – at Washington, 4:30 p.m. July 24 – at Connecticut, 4 p.m. July 26 – at New York, 4 p.m. July 29 – vs. Las Vegas, 7 p.m. Aug. 1 – at Seattle, 7 p.m. Aug. 5 – vs. Indiana, 7 p.m. Aug. 7 – vs. Connecticut, 7 p.m. Aug. 9 – at Golden State, noon Aug. 10 – vs. Seattle, 3 p.m. Aug. 12 – vs. New York, 7 p.m. Aug. 15 – at Dallas, 4:30 p.m. Aug. 17 – at Washington, Noon Aug. 20 – vs. Dallas, 7 p.m. Aug. 26 – Phoenix, 7 p.m. Aug. 29 – vs. Indiana, 7 p.m. Aug. 31 – vs. Washington, 5 p.m. Sept. 1 – at Seattle, 7 p.m. Sept. 3 – at Atlanta, 4:30 p.m. Sept. 5 – at Atlanta, 4:30 p.m. Sept. 7 – vs. Dallas, 3 p.m. Sept. 9 – at Atlanta, 7 p.m. Sept. 11 – vs. Las Vegas, 7 p.m.
The new Meta-owned social app recently added the option to add more threads columns, and users can now set one of their new columns as a default. In a new post on Threads, Mark Zuckerberg said that the app is currently testing the ability to let users pick any of the custom feeds that they’ve created, or the following feed as their default. I’d love to be able to do this with my custom tech feeds, but as of the time of writing, neither my Android nor iOS apps seem to have gotten the update. Zuckerberg says that the app is also going to make the ability to see and customize these new feed options more visible in the app to see if that makes users pick it up faster. I think this part is the more important of the two new sides of this test since most people probably still don’t even know that you can create custom feeds. The Verge says that if you have been randomly selected to participate in the test, you can press and hold on the name of the feed you want to be your default. An option to ‘edit feeds’ appears, and you can drag the feed you want to be your default to the top of the list. Overall, this is an exciting update, and to me, it sounds like a feature Threads should have had a long time ago. Hopefully, this test goes well, and then it will roll out to all users since I believe the ability to tailor your social media experience to your interests goes a long way toward making it engaging. Source: Mark Zuckerberg , The Verge Image source: Shutterstock